Dr. Lal Path Labs Ltd. has informed the Exchange that Record date for the purpose of Dividend is 06-Jun-2025.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Smallcap 250 and 0.5 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Lal Path Labs announced audited consolidated results for Q4 and FY ended March 31, 2025. FY25 revenue from operations rose to INR 24,614 million from INR 22,266 million (~10.5% YoY), while net profit jumped to INR 4,922 million from INR 3,623 million (~36% YoY). Q4 FY25 revenue stood at INR 6,026 million (vs INR 5,454 million in Q4 FY24) and Q4 profit was INR 1,555 million (vs INR 858 million). The Board recommended a final dividend of INR 6 per share (60% on face value of INR 10), taking total FY25 dividend to INR 24 per share. Record date is June 6, 2025. Prior-year figures were restated to reflect the amalgamation of Paliwal Medicare into Paliwal Diagnostics. Deloitte issued an unmodified audit opinion.
Strong profit growth (36% YoY) and steady dividend of INR 24/share should be positive for shareholders, though revenue growth was modest at ~10%. The restatement of prior-year numbers and a one-time deferred tax credit of INR 408 million from the Suburban Diagnostics liquidation boosted bottom-line growth.